🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

We reported Q4 and full-year 2024 financial results and highlighted our expected upcoming milestones. Read our latest press release here: bit.ly/4l6543N

Our Medical Affairs team recently participated in this year’s meeting of the Medical Affairs Professional Society, sharing their insights into patient engagement & the challenges of creating effective and strategic #MedicalAffairs roadmaps. #MAPS2025 #RareResolve MAPS

Our CEO Paula Ragan was a guest on @BiotechTVHQ where she spoke about her career and path to founding X4, as well as our progress so far. Check out the video below!

Our Chief Medical Officer Christophe Arbet-Engels, M.D., Ph.D. recently chaired a Track at the #CMOSummit360 in Boston, leading a panel on “What CEOs Wish CMOs Knew” and sessions on effectively working with consultants and building CMO teams. #BiotechLeadership #RareResolve

Celebrating World Primary Immunodeficiency Week a little differently this year – the 1st anniversary of our approved product – renewing our #RareResolve to improve the lives of those with rare PIs AND celebrating our patients’ successes. #WHIMsyndrome #WorldPIWeek

We will report first-quarter financial results and host a conference call and webcast on May 1, 2025. More in today’s release: bit.ly/4iBmpiz

This World Primary Immunodeficiency Week, X4 remains committed to raising awareness of WHIM syndrome, a diagnosable and treatable combined PI. Learn about its distinct underlying cause, CXCR4 pathway dysregulation. Connect with us CIS on May 1–4. #WorldPIWeek #CIS

Our VP of Sales & Marketing recently hosted a fireside chat with Medical Publisher CheckRare at #WorldOrphanUSA, a forum focused on advancing orphan drug development and enhancing access to life-saving therapies for #raredisease. #WHIMsyndrome #RareResolve World Orphan Drug Congress USA

We reported first quarter 2025 financial results and provided corporate updates. Read our latest press release here: bit.ly/4mdY3hZ and listen to the related webcast at bit.ly/4cWBrOx.

Did You Know? In WHIM syndrome, there is a reported median 5-year delay between the onset of symptoms and diagnosis, and for these patients, a 27% incidence of end-organ damage. Find us American Society of Pediatric Hematology/Oncology Booth 307 to learn about earlier diagnosis in pediatric patients.

Our CEO Paula Ragan highlighted X4’s success in developing and launching our novel rare disease therapy XOLREMDI® in a session on “Getting Breakthrough Science into the Market” during this year’s Convergence Forum for leaders in healthcare innovation. #CVFORUM25 #RareResolve

That’s a wrap for X4 at the 2025 American Society of Pediatric Hematology/Oncology Conference! We’ve enjoyed our discussions with HCPs about their approaches to diagnosing and managing WHIM syndrome. Our mission to drive early diagnosis continues—find resources at bit.ly/4kiobGE. #ASPHO2025

At the upcoming European Hematology Association Congress between June 12–15, we’ll present data from our Phase 2 trial in chronic #neutropenia — our first time sharing these results with the #hematology community. Learn more about our participation: bit.ly/3S4PND2 #EHA2025

Did You Know? The Immune Deficiency Foundation reports that most patients with WHIM syndrome are first diagnosed with CVID. X4 is excited to announce the launch of WHIMsyndrome.com, where patients with questions about their immune deficiency may find answers: bit.ly/4htAkXh.

We're proud to receive the 2025 Industry Innovation Award presented by National Organization for Rare Disorders (NORD) (NORD)! At X4, we're driving progress for people living with rare immune disorders through our medicines and by advocating for the needs of patients. rareimpact.org #RareDiseases

Thrilled to share the U.S. FDA has granted #FastTrackdesignation to mavorixafor for the treatment of chronic #neutropenia (CN). Mavorixafor is currently in a Phase 3 clinical trial (4WARD) in certain primary CN conditions. Learn more in today’s release: bit.ly/45Q1Pbk

We presented positive data from our completed Phase 2 trial of mavorixafor for the treatment of chronic #neutropenia (CN) at the European Hematology Association Congress. Review the data in today’s press release: bit.ly/4mUAtH8 #EHA2025

ICYMI – our CFO, Adam Mostafa, was recently interviewed by Informa Connect – learn more about his unique journey from Wall Street to biotech: bit.ly/4nB32tq

Proud to launch our WHIM Syndrome Patient Education Program at this year’s Neutropenia Network Conference highlighting the importance of genetic testing and early diagnosis to support improved health outcomes. #WHIMsyndrome whimsyndrome.com

Our CEO Dr. Paula Ragan recently engaged in a fireside chat with Jeanne Siegel, head of the Neutropenia Network, focused on X4’s efforts to expand treatment options for those with chronic neutropenic conditions. #neutropenia #RareResolve